Compounds > N-(4,6-dimethyl-2-pyridinyl)-4-[5-(trifluoromethyl)-2-pyridinyl]-1-piperazinecarbothioamide
Page last updated: 2024-11-13

N-(4,6-dimethyl-2-pyridinyl)-4-[5-(trifluoromethyl)-2-pyridinyl]-1-piperazinecarbothioamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID49853368
CHEMBL ID2135970
CHEBI ID92220
SCHEMBL ID17927265

Synonyms (17)

Synonym
NCGC00242267-03
NCGC00242267-02
nct-502 ,
NCGC00242267-01 ,
CHEMBL2135970
bdbm195605
n-(4,6-dimethylpyridin-2-yl)-4-[5-(trifluoromethyl)pyridin-2-yl]piperazine-1-carbothioamide
SCHEMBL17927265
CHEBI:92220
Q27163989
1542213-00-2
n-(4,6-dimethyl-2-pyridinyl)-4-[5-(trifluoromethyl)-2-pyridinyl]-1-piperazinecarbothioamide
CS-0064503
MS-26655
HY-117240
hhkppmsupatmkp-uhfffaoysa-n
AKOS040742274
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
piperazines
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency12.45530.141337.9142100.0000AID540350; AID540352; AID540353; AID540355; AID602360; AID602362; AID602366; AID602370; AID602373
Aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency10.53801.91827.670117.0961AID743195
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
D-3-phosphoglycerate dehydrogenaseHomo sapiens (human)IC50 (µMol)3.70003.70003.70003.7000AID1431407; AID1494475; AID1801988
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (21)

Processvia Protein(s)Taxonomy
glutamine metabolic processD-3-phosphoglycerate dehydrogenaseHomo sapiens (human)
glycine metabolic processD-3-phosphoglycerate dehydrogenaseHomo sapiens (human)
L-serine biosynthetic processD-3-phosphoglycerate dehydrogenaseHomo sapiens (human)
threonine metabolic processD-3-phosphoglycerate dehydrogenaseHomo sapiens (human)
brain developmentD-3-phosphoglycerate dehydrogenaseHomo sapiens (human)
gamma-aminobutyric acid metabolic processD-3-phosphoglycerate dehydrogenaseHomo sapiens (human)
regulation of gene expressionD-3-phosphoglycerate dehydrogenaseHomo sapiens (human)
taurine metabolic processD-3-phosphoglycerate dehydrogenaseHomo sapiens (human)
spinal cord developmentD-3-phosphoglycerate dehydrogenaseHomo sapiens (human)
glial cell developmentD-3-phosphoglycerate dehydrogenaseHomo sapiens (human)
neural tube developmentD-3-phosphoglycerate dehydrogenaseHomo sapiens (human)
neuron projection developmentD-3-phosphoglycerate dehydrogenaseHomo sapiens (human)
G1 to G0 transitionD-3-phosphoglycerate dehydrogenaseHomo sapiens (human)
very long-chain fatty acid metabolic processPeroxisomal multifunctional enzyme type 2Homo sapiens (human)
osteoblast differentiationPeroxisomal multifunctional enzyme type 2Homo sapiens (human)
fatty acid beta-oxidationPeroxisomal multifunctional enzyme type 2Homo sapiens (human)
androgen metabolic processPeroxisomal multifunctional enzyme type 2Homo sapiens (human)
estrogen metabolic processPeroxisomal multifunctional enzyme type 2Homo sapiens (human)
very long-chain fatty-acyl-CoA metabolic processPeroxisomal multifunctional enzyme type 2Homo sapiens (human)
medium-chain fatty-acyl-CoA metabolic processPeroxisomal multifunctional enzyme type 2Homo sapiens (human)
Sertoli cell developmentPeroxisomal multifunctional enzyme type 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
electron transfer activityD-3-phosphoglycerate dehydrogenaseHomo sapiens (human)
L-malate dehydrogenase activityD-3-phosphoglycerate dehydrogenaseHomo sapiens (human)
NAD bindingD-3-phosphoglycerate dehydrogenaseHomo sapiens (human)
phosphoglycerate dehydrogenase activityD-3-phosphoglycerate dehydrogenaseHomo sapiens (human)
3-hydroxyacyl-CoA dehydrogenase activityPeroxisomal multifunctional enzyme type 2Homo sapiens (human)
enoyl-CoA hydratase activityPeroxisomal multifunctional enzyme type 2Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activityPeroxisomal multifunctional enzyme type 2Homo sapiens (human)
isomerase activityPeroxisomal multifunctional enzyme type 2Homo sapiens (human)
3-hydroxyacyl-CoA dehydratase activityPeroxisomal multifunctional enzyme type 2Homo sapiens (human)
3alpha,7alpha,12alpha-trihydroxy-5beta-cholest-24-enoyl-CoA hydratase activityPeroxisomal multifunctional enzyme type 2Homo sapiens (human)
protein homodimerization activityPeroxisomal multifunctional enzyme type 2Homo sapiens (human)
(3R)-hydroxyacyl-CoA dehydrogenase (NAD+) activityPeroxisomal multifunctional enzyme type 2Homo sapiens (human)
17-beta-hydroxysteroid dehydrogenase (NAD+) activityPeroxisomal multifunctional enzyme type 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
cytosolD-3-phosphoglycerate dehydrogenaseHomo sapiens (human)
extracellular exosomeD-3-phosphoglycerate dehydrogenaseHomo sapiens (human)
peroxisomePeroxisomal multifunctional enzyme type 2Homo sapiens (human)
peroxisomal membranePeroxisomal multifunctional enzyme type 2Homo sapiens (human)
peroxisomal matrixPeroxisomal multifunctional enzyme type 2Homo sapiens (human)
cytosolPeroxisomal multifunctional enzyme type 2Homo sapiens (human)
membranePeroxisomal multifunctional enzyme type 2Homo sapiens (human)
peroxisomePeroxisomal multifunctional enzyme type 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID540352qHTS for Inhibitos of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase): Chemistry Optimization Followup in B. Subtilis 1682001The Journal of biological chemistry, Oct-05, Volume: 276, Issue:40
4'-phosphopantetheine transfer in primary and secondary metabolism of Bacillus subtilis.
AID1494476Inhibition of N-terminal His6-tagged human liver PHGDH expressed in Escherichia coli Rosetta (DE3)pLysS at 57 uM using 3-phosphoglycerate as substrate after 20 mins in presence of NAD+ by resazurin fluorescence based PSAT1/diaphorase/PSPH coupled enzyme a2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitors.
AID1494477Half life in rat liver microsomes at 1 uM at 37 degC in presence of NADPH regeneration system incubated for 15 mins by LC-MS/MS analysis2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitors.
AID1074989Antibacterial activity against Bacillus subtilis HM489 assessed as cellular ATP content after 5 hrs by BacTiter-Glo assay2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
4-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide (ML267), a potent inhibitor of bacterial phosphopantetheinyl transferase that attenuates secondary metabolism and thwarts bacterial growth.
AID1494478Kinetic solubility pH 7.4 buffer at 150 uM after 6 hrs by saturation shake-flask solubility method2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitors.
AID1431407Inhibition of human liver N-terminal His6-tagged PHGDH expressed in Escherichia coli Rosetta (DE3)pLysS using 3 -phosphoglycerate as substarte measured at 20 mins by resazurin based diaphorase coupled assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Challenges and Opportunities in the Development of Serine Synthetic Pathway Inhibitors for Cancer Therapy.
AID1494479Cytotoxicity against human MDA-MB-468 cells2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitors.
AID1494480Inhibition of PHGDH in human MDA-MB-468 cells assessed as decrease in serine flux2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitors.
AID1074997Inhibition of Bacillus subtilis AcpS-PPTase using rhodamine-CoA/BHQ-2-YbbR as substrate preincubated for 15 mins followed by substrate addition by HTS assay2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
4-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide (ML267), a potent inhibitor of bacterial phosphopantetheinyl transferase that attenuates secondary metabolism and thwarts bacterial growth.
AID1494475Inhibition of N-terminal His6-tagged human liver PHGDH expressed in Escherichia coli Rosetta (DE3)pLysS using 3-phosphoglycerate as substrate after 20 mins in presence of NAD+ by resazurin fluorescence based PSAT1/diaphorase/PSPH coupled enzyme assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitors.
AID1074991Inhibition of Bacillus subtilis Sfp-PPTase using rhodamine-CoA/BHQ-2-YbbR as substrate preincubated for 15 mins followed by substrate addition by HTS assay2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
4-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide (ML267), a potent inhibitor of bacterial phosphopantetheinyl transferase that attenuates secondary metabolism and thwarts bacterial growth.
AID1074990Cytotoxicity against human HepG2 cells assessed as cellular ATP content after 48 hrs by CellTiter-Glo assay2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
4-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide (ML267), a potent inhibitor of bacterial phosphopantetheinyl transferase that attenuates secondary metabolism and thwarts bacterial growth.
AID1494481Aqueous solubility of the compound2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitors.
AID1801988PHGDH Inhibition Assay from Article 10.1038/nchembio.2070: \\A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate.\\2016Nature chemical biology, 06, Volume: 12, Issue:6
A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.28 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chloramphenicol
Amphenicol: Chloramphenicol and its derivatives.		2.110C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
cetrimonium bromide
cetyltrimethylammonium bromide : The organic bromide salt that is the bromide salt of cetyltrimethylammonium; one of the components of the topical antiseptic cetrimide.		2.110organic bromide salt;
quaternary ammonium salt		detergent;
surfactant
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		2.110glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
adenosine 3'-phosphate-5'-phosphate
adenosine 3',5'-bismonophosphate : An adenosine bisphosphate having two monophosphate groups at the 3'- and 5'-positions.		2.110adenosine bisphosphateEscherichia coli metabolite;
mouse metabolite
sch-202676
SCH-202676: An allosteric modulator of both agonist and antagonist binding to G protein-coupled receptors; structure in first source		2.110
N-(4-methyl-2-pyridinyl)-4-[3-(trifluoromethyl)anilino]-1-piperidinecarbothioamide
[no description available]		2.4420(trifluoromethyl)benzenes
4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-n-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide
4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide: inhibits phosphopantetheinyl transferase; structure in first source		2.4420
ConditionIndicatedRelationship StrengthStudiesTrials
Experimental Mammary Neoplasms
[description not available]		02.1310
Benign Neoplasms
[description not available]		03.0610
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.0610